AI-Based Precision Transfusion Prediction Model in Critically Ill Patients

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSecond Affiliated Hospital, Zhejiang University, School of Medicine

About this trial

This multicenter observational study aims to develop and validate an artificial intelligence-based precision transfusion prediction model for critically ill patients. The study will collect clinical characteristics, laboratory parameters, transfusion-related information, physiological data, and clinical outcomes from critically ill patients admitted to intensive care units. An AI model will be developed using retrospective data and further evaluated using prospective observational data. The primary objective is to investigate factors associated with multiple organ dysfunction syndrome (MODS) and establish a predictive model to support individualized transfusion management in critically ill patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adult patients (aged ≥18 years) admitted to the intensive care unit.

Patients with available clinical data, including demographic characteristics, laboratory parameters, transfusion-related information, and clinical outcomes.

Patients meeting the requirements for model development and analysis.

Disqualifiers

Patients younger than 18 years.

Patients with missing key clinical information required for analysis.

Patients with repeated ICU admissions during the study period (only the first ICU admission will be included).

Patients whose data cannot be used for research purposes according to ethical requirements.

Trial population

This study includes adult critically ill patients admitted to intensive care units. Clinical data including demographic characteristics, underlying diseases, severity indicators, laboratory parameters, transfusion-related information, and clinical outcomes will be collected from electronic medical records. The study population will be used to develop an artificial intelligence-based prediction model for precision transfusion management and risk assessment of multiple organ dysfunction syndrome in critically ill patients.

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

  • Red Blood Cell Transfusion Exposure

    Other intervention

    Red blood cell transfusion exposure refers to the receipt of red blood cell transfusion during intensive care hospitalization. Transfusion-related information, including transfusion status, number of transfused units, and cumulative transfusion volume, will be collected from routine clinical care records. Transfusion decisions are not assigned by the study protocol, and no intervention is performed as part of this observational study.

Treatment groups

2,598 Participants
are divided into 1 treatment group
Group A: Critically Ill Patient Cohort1 intervention

Trial outcomes

Primary outcomes

1

Occurrence of Multiple Organ Dysfunction Syndrome (MODS)

The primary outcome is the occurrence of multiple organ dysfunction syndrome (MODS) during intensive care unit hospitalization. MODS will be defined according to clinical diagnostic criteria based on dysfunction of two or more organ systems.

Time frame
During ICU hospitalization (up to 28 days after ICU admission)

Secondary outcomes

1

ICU Mortality

Death occurring during the intensive care unit stay.

Time frame
Up to Day 28 after ICU admission
2

Hospital Mortality

Death occurring during the index hospitalization

Time frame
Up to Day 28 after ICU admission

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: